{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107008","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.069258+00:00","generated_at":"2026-05-17T00:18:49.973131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026","bullets":["Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.","Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.","SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.","LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.","$12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107008","json":"https://secwatch.observer/filing/0001104659-25-107008.json","markdown":"https://secwatch.observer/filing/0001104659-25-107008.md","text":"https://secwatch.observer/filing/0001104659-25-107008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/0001104659-25-107008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/nxtc-20251105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:49.973131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}